Alnylam Pharmaceuticals (ALNY) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 293.4% versus a loss of 50.2%. Over five years, RVMD leads with a +598.0% price change compared with +7.7% for ALNY. Revolution Medicines is the larger company by market cap ($40.67 billion vs $31.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | RVMD |
|---|---|---|
| Share price | $232.68 | $189.76 |
| Market cap | $31.13B | $40.67B |
| 1-day change | +3.63% | +0.87% |
| YTD return | -43.54% | +136.18% |
| 1-year return | -50.18% | +293.39% |
| 5-year return | +7.66% | +598.03% |
| P/E ratio (TTM) | 39.24 | — |
| Forward P/E | 18.73 | — |
| EPS (TTM) | $5.93 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $0 |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | $-1.13B |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $495.55 | $224.31 |
| 52-week low | $197.81 | $47.28 |
| Distance from 52-week high | -53.05% | -15.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +59.50% | +36.40% |
| Average volume | 1.78M | 1.93M |
| Shares outstanding | 133.81M | 214.34M |
| Employees | 2,500 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVMD has outperformed ALNY by 343.6 percentage points over the past year.
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
ALNY vs RVMD FAQ
Which is bigger, Alnylam Pharmaceuticals or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.67B compared with $31.13B for Alnylam Pharmaceuticals (ALNY).
Which stock has performed better over the past year, ALNY or RVMD?
RVMD returned +293.39% over the past 12 months, compared with -50.18% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and Revolution Medicines in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alnylam Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Revolution Medicines.